Long-acting HIV prevention shot study
Part of Infections clinical trials.
This study looks at a long-acting injectable HIV prevention medication (called cabotegravir) to see how well it works in real life. If you are already taking or starting this shot, you may be able to join and help improve HIV prevention care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are receiving care at an NHS sexual health clinic
- You are prescribed or already using the long-acting HIV prevention injection (cabotegravir)
- Your HIV test is negative when you start the injection
- You are willing to give informed consent and follow study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
Hear when a new PrEP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.